Bjørn Moum, Professor & Consultant
Universitetet i Oslo
H-index: 66
Europe-Norway
Top articles of Bjørn Moum, Professor & Consultant
Title | Journal | Author(s) | Publication Date |
---|---|---|---|
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study | Crohn's & Colitis 360 | Thea H Wiken Marte L Høivik Karoline Anisdahl Lydia Buer David J Warren | 2024/1/1 |
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study | Digestive and Liver Disease | Karoline Anisdahl Sandre Svatun Lirhus Asle W Medhus Bjørn Moum Hans Olav Melberg | 2024/3/2 |
The impact of restrictions on psychological outcomes in patients with inflammatory bowel disease on biological treatment during the coronavirus pandemic in Norway | Quality of Life Research | Randi Opheim Kristian Marling Moum Milada Cvancarova Småstuen Bjørn Moum | 2023/3 |
P860 The Costs of Inflammatory Bowel Diseases in High-Income Settings | Journal of Crohn's and Colitis | J Burisch M Zhao S Odes P De Cruz S Vermeire | 2023/2/1 |
Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study) | Scandinavian Journal of Gastroenterology | Benoit Follin-Arbelet Milada Cvancarova Småstuen Øistein Hovde Lars-Petter Jelsness-Jørgensen Bjørn Moum | 2023/11/2 |
P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn’s Disease (CD): Results from a large multinational prospective … | Journal of Crohn's and Colitis | E Louis S Sebastien B Siegmund P Bossuyt S Danese | 2023/2/1 |
Risk of cancer in patients with Crohn’s disease 30 years after diagnosis (the IBSEN study) | Crohn's & Colitis 360 | Benoit Follin-Arbelet Milada Cvancarova Småstuen Øistein Hovde Lars-Petter Jelsness-Jørgensen Bjørn Moum | 2023/10/1 |
P882 Regional differences in biologic and surgical treatment of inflammatory bowel disease in Norway 2011–2019 | Journal of Crohn's and Colitis | K Anisdahl SS Lirhus AW Medhus B Moum HO Melberg | 2023/2/1 |
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring | Scandinavian Journal of Gastroenterology | Thea H Wiken Marte L Høivik Lydia Buer David J Warren Nils Bolstad | 2023/8/3 |
Mortality in patients with inflammatory bowel disease: results from 30 years of follow-up in a Norwegian Inception Cohort (the IBSEN study) | Journal of Crohn's and Colitis | Benoit Follin-Arbelet Milada Cvancarova Småstuen Øistein Hovde Lars-Petter Jelsness-Jørgensen Bjørn Moum | 2023/4/1 |
Iron deficiency in patients with acute and chronic heart failure-a simple algoritm | Lakartidningen | Stefan Lindgren Henrik Hjortswang Björn Moum Peter Vasko Lars H Lund | 2022/9/21 |
P636 Work disability after 20 years with Inflammatory Bowel Disease-results from the IBSEN study | Journal of Crohn's and Colitis | C Lund VA Kristensen IL Monstad IC Solberg Ø Hovde | 2022/1/1 |
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory … | Ashwin N Ananthakrishnan Gilaad G Kaplan Charles N Bernstein Kristin E Burke Paul J Lochhead | 2022/7/1 | |
The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients | Scandinavian Journal of Gastroenterology | Lars-Petter Jelsness-Jørgensen Bjørn Moum Tore Grimstad Jørgen Jahnsen Øistein Hovde | 2022/2/4 |
Bedömning och behandling av järnbrist hos hjärtsviktspatienter:[Iron deficiency in patients with acute and chronic heart failure-a simple algoritm] | Läkartidningen | Stefan Lindgren Henrik Hjortswang Björn Moum Peter Vasko Lars H Lund | 2022 |
S972 The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD | Official journal of the American College of Gastroenterology| ACG | Jamie Horrigan Edouard Louis Antonino Spinelli Simon Travis Bjørn Moum | 2022/10/1 |
Serologic Response to Sars-Cov-2 Vaccination in Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy: Association to Disease Type and Serum Drug Levels | United European Gastroenterology Journal | KK Jorgensen ML Hoivik A Chopra JS Benth P Ricanek | 2022 |
Real world data on treatment success and drug persistence in anti-TNF therapy for ulcerative colitis | JA Lundekvam ML Hoivik K Anisdahl B Moum AW Medhus | 2021/5/1 | |
Incidence and prevalence of inflammatory bowel disease in Norway and the impact of different case definitions: a nationwide registry study | Frontline Gastroenterology | Ben Hamilton Harry Green Neel Heerasing Peter Hendy Lucy Moore | 2021/11/1 |
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study | Scandinavian Journal of Gastroenterology | Karoline Anisdahl Sandre Svatun Lirhus Asle W Medhus Bjørn Moum Hans Olav Melberg | 2021/10/3 |